Peer-Reviewed Publications

    Reactive oxygen species in the adverse outcome pathway framework: Toward creation of harmonized consensus key events

    Tanabe, S.; O'Brien, J.; Tollefsen, K. E.; Kim, Y.; Chauhan, V.; Yauk, C.; Huliganga, E.; Rudel, R. A.; Kay, J. E.; Helm, J. S.; Beaton, D.; Filipovska, J.; Sovadinova, I.; Garcia-Reyero, N.; Mally, A.; Sos Poulsen, S.; Delrue, N.; Fritsche, E.; Luettich, K.; La Rocca, C.; Yepiskoposyan, H.; Klose, J.; Hogh Danielsen, P.; Esterhuizen, M.; Raun Jacobsen, N.; Vogel, U.; Gant, T. W.; Choi, I.; FitzGerald, R.

    Published
    Jul 6, 2022
    DOI
    10.3389/ftox.2022.887135
    PMID
    35875696
    Link to publication
    Topic
    Summary

    Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are formed as a result of natural cellular processes, intracellular signaling, or as adverse responses associated with diseases or exposure to oxidizing chemical and non-chemical stressors. The action of ROS and RNS, collectively referred to as reactive oxygen and nitrogen species (RONS), has recently become highly relevant in a number of adverse outcome pathways (AOPs) that capture, organize, evaluate and portray causal relationships pertinent to adversity or disease progression. RONS can potentially act as a key event (KE) in the cascade of responses leading to an adverse outcome (AO) within such AOPs, but are also known to modulate responses of events along the AOP continuum without being an AOP event itself. A substantial discussion has therefore been undertaken in a series of workshops named “Mystery or ROS” to elucidate the role of RONS in disease and adverse effects associated with exposure to stressors such as nanoparticles, chemical, and ionizing and non-ionizing radiation. This review introduces the background for RONS production, reflects on the direct and indirect effects of RONS, addresses the diversity of terminology used in different fields of research, and provides guidance for developing a harmonized approach for defining a common event terminology within the AOP developer community.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.